 |
|
Nonsurgical Repigmentation Therapies in Vitiligo
Meta-analysis of the Literature
M. D. Njoo, MD;
P. I. Spuls, MD;
J. D. Bos, MD, PhD;
W. Westerhof, MD, PhD;
P. M. M. Bossuyt, MD, PhD
Arch Dermatol. 1998;134:1532-1540.
Objective To assess the effectiveness and safety of nonsurgical repigmentation therapies in localized and generalized vitiligo by means of a meta-analysis.
Data Sources Computerized searches of bibliographic databases, a complementary manual literature search, and contacts with researchers and pharmaceutical firms.
Study Selection Predefined selection criteria were applied to both randomized and nonrandomized controlled trials.
Data Extraction Two investigators independently assessed the articles for inclusion. When there was a disagreement, a third investigator was consulted.
Data Synthesis Sixty-three studies were found on therapies for localized vitiligo. Of these, 10 of 11 randomized controlled trials and 29 of 110 patient series were included. One hundred seventeen studies on therapies for generalized vitiligo were found. Of these, 10 of 22 randomized controlled trials and 46 of 231 patient series were included. Among randomized controlled trials on localized vitiligo, the pooled odds ratio vs placebo was significant for topical class 3 corticosteroids (14.32; 95% confidence interval [CI], 2.45-83.72). In the patient series, topical class 3 and class 4 corticosteroids carried the highest mean success rates (56% [95% CI, 50%-62%] and 55% [95% CI, 49%-61%], respectively). Side effects were reported mostly with topical psoralen and intralesional and class 4 corticosteroids. In the randomized controlled trials on generalized vitiligo, the odds ratio vs placebo was significant for oral methoxsalen plus sunlight (23.37; 95% CI, 1.33-409.93), oral psoralen plus sunlight (19.87; 95% CI, 2.37-166.32), and oral trioxsalen plus sunlight (3.75; 95% CI, 1.24-11.29). In the series, the highest mean success rates were achieved with narrowband UV-B (63%; 95% CI, 50%-76%), broadband UV-B (57%; 95% CI, 29%-82%), and oral methoxsalen plus UV-A therapy (51%; 95% CI, 46%-56%). Oral methoxsalen plus UV-A was associated with the highest rates of side effects. No side effects were reported with UV-B therapy.
Conclusions Class 3 corticosteroids and UV-B therapy are the most effective and safest therapies for localized and for generalized vitiligo, respectively.
From the Netherlands Institute for Pigmentary Disorders (Drs Njoo and Westerhof) and the Departments of Dermatology (Drs Spuls, Bos, and Westerhof) and Clinical Epidemiology and Biostatistics (Dr Bossuyt), Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
RELATED ARTICLE
Archives of Dermatology Reader's Choice: Continuing Medical Education
Arch Dermatol. 1998;134(12):1640-1641.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
New Insights and New Therapies in Vitiligo
Grimes
JAMA 2005;293:730-735.
FULL TEXT
Double-blind Placebo-Controlled Study of Autologous Transplanted Epidermal Cell Suspensions for Repigmenting Vitiligo
van Geel et al.
Arch Dermatol 2004;140:1203-1208.
ABSTRACT
| FULL TEXT
Topical Tacrolimus and the 308-nm Excimer Laser: A Synergistic Combination for the Treatment of Vitiligo
Passeron et al.
Arch Dermatol 2004;140:1065-1069.
ABSTRACT
| FULL TEXT
Parametric Modeling of Narrowband UV-B Phototherapy for Vitiligo Using a Novel Quantitative Tool: The Vitiligo Area Scoring Index
Hamzavi et al.
Arch Dermatol 2004;140:677-683.
ABSTRACT
| FULL TEXT
Erbium:YAG Laser and Cultured Epidermis in the Surgical Therapy of Stable Vitiligo
Guerra et al.
Arch Dermatol 2003;139:1303-1310.
ABSTRACT
| FULL TEXT
A Double-blind Randomized Trial of 0.1% Tacrolimus vs 0.05% Clobetasol for the Treatment of Childhood Vitiligo
Lepe et al.
Arch Dermatol 2003;139:581-585.
ABSTRACT
| FULL TEXT
Childhood Vitiligo and Tacrolimus: Immunomodulating Treatment for an Autoimmune Disease
Plettenberg et al.
Arch Dermatol 2003;139:651-654.
FULL TEXT
What Proportion of Dermatological Patients Receive Evidence-Based Treatment?
Abeni et al.
Arch Dermatol 2001;137:771-776.
ABSTRACT
| FULL TEXT
Treatment of "Stable" Vitiligo by Timedsurgery and Transplantation of Cultured Epidermal Autografts
Guerra et al.
Arch Dermatol 2000;136:1380-1389.
ABSTRACT
| FULL TEXT
Guidelines for Treatment of Vitiligo: Is an Update Pending If Recommendations for Children Are Not Followed?
Mohrenschlager et al.
Arch Dermatol 2000;136:1173-1174.
FULL TEXT
The Development of Guidelines for the Treatment of Vitiligo
Njoo et al.
Arch Dermatol 1999;135:1514-1521.
ABSTRACT
| FULL TEXT
|
